

## Communicable Reportable Conditions

Effective October 15, 2021

Confidential fax: 303-782-0338 STI/HIV confidential fax:303-782-5393 Toll-free fax: 800-811-7263

Phone: 303-692-2700 Toll-free phone: 800-866-2759 Evenings/weekends: 303-370-9395 How to report: cdphe.colorado.gov/report-a-disease

· Disease report forms

Specimen submission guidance
 Colorado Electronic Disease Reporting System (CEDRS) application

Complete Board of Health rules can be found at: cdphe.colorado.gov/ all-regulations/regulations-adopted-by-the-board-of-health

### Immediate reporting by phone is required of any illness that may be caused by biological, chemical or radiologic terrorism.

As indicated below, reporting by labs (diagnostic results and those highly correlated with disease) and providers (including suspected conditions) is required in accordance with Regulation 6 CCR 1009-1. In addition to reporting positive laboratory results to public health, clinical laboratories are required to submit isolates and/or clinical material to the CDPHE laboratory for select pathogens. For all other pathogens, isolate/clinical material submission may be requested.

		, , ,			
Time	Rep		Time	Rep	
4d	L	Acinetobacter baumannii, carbapenem-resistant (CRAB)*	4d	Р	Influenza-associated death if <18 years
4d	P	Acute flaccid myelitis	4d	L&P	Influenza-associated hospitalization
24h	Р	Animal bites	4d	L&P	Legionellosis
		(by dogs, cats, rabies reservoir species & other wild carnivores)	4d	Р	Leprosy (Hansen's Disease)
4d	Р	Animal bites (by any other mammals)	4d	L&P	Listeriosis*
lmm	L&P	Anthrax*	4d	L&P	Lyme disease
4d	L	Arboviral Diseases	4d	L&P	Lymphogranuloma venereum (LGV) <sup>♥</sup>
		(Eastern equine encephalitis, LaCrosse encephalitis virus, Japanese	4d	L&P	Malaria
		encephalitis virus, California encephalitis serogroup, St. Louis encephalitis virus, Western equine encephalitis virus, Powassan virus and others)	Imm	L&P	Measles (rubeola)
lmm	L&P	Botulism	Imm	L&P	Meningococcal Disease (N. meningitidis or gm-neg diplococci)*
4d	L&P		4d	Р	Multisystem Inflamatory Syndrome in Children (MIS-C) if <21 years
4d	L&P	Campylobacteriosis	4d	L&P	Mumps
lmm	L&P	Candida auris (identified or suspected, including Candida haemulonii)*	30d	L	Mycobacterium, nontuberculous (NTM) 5-county
30d	L	Candidemia 5-county	Imm	L&P	Outbreaks (all types, including foodborne, water, person-to-person
4d	L&P	Chancroid <sup>◊</sup>	1		healthcare settings)
4d	L	Chikungunya	1wd	L&P	Pertussis (whooping cough)
4d	L&P	Chlamydia <sup>♦</sup>	lmm		Plague*
lmm	L&P	Cholera*	Imm	L&P	Poliomyelitis
4d	Р	CJD & other transmissible spongiform encephalopathies (TSEs)	4d	L	Pseudomonas aeruginosa, carbapenem-resistant
30d	L	Clostridioides difficile 5-county	4d	L&P	Psittacosis
4d	L	Colorado tick fever	4d	L&P	Q fever (Coxiella burnetii)
1wd	I & P	COVID-19 (SARS-COV-2 positive result on any test type and COVID-19	Imm	L&P	Rabies, human (suspected)
1774	Lu.	lineage or sequencing)	4d	L&P	Respiratory Syncytial Virus (RSV)-associated hospitalization 5-county
1wd	L&P	COVID-19 (SARS-COV-2 negative or inconclusive result on any test type)	4d	L&P	Rickettsiosis (including RMSF and typhus)
lmm		Coronavirus, severe or novel (MERS-CoV or SARS-CoV)	1wd	L&P	Rubella, acute infection
4d	L&P	Cryptosporidiosis	4d	L&P	Rubella, congenital
4d	L&P	Cyclosporiasis	4d	L&P	Salmonellosis*
4d	L	Dengue	4d	L&P	Shigellosis*
lmm	L&P	Diphtheria*	Imm	L&P	Smallpox (Variola virus or Orthopox virus)
4d	Р	Encephalitis	4d	L	Staphylococcus aureus, Vancomycin-resistant/intermediate(VRSA/
4d	L	Enterobacteriaceae, carbapenem-resistant (CRE)*	ĺ	_	VISA)*
4d	L	Enterobacteriaceae, extended-spectrum	4d	Р	Streptococcal toxic shock syndrome**
		beta-lactamase (ESBL) Boulder	4d	L	Streptococcus pneumoniae** †
4d	L&P	Escherichia coli O157:H7 / Shiga toxin-producing Escherichia coli*	1wd	L&P	Syphilis/ <i>Treponema pallidum</i> (all reactive tests) <sup>◊</sup>
4d		Giardiasis	4d	Р	Tetanus
4d	L&P	Gonorrhea, any site <sup>0</sup>	4d	L&P	Tick-borne relapsing fever (Borrelia hermsii, Borrelia parkeri or
4d	L	Group A streptococci* † 5-county	İ		Borrelia turicatae)
30d	L	Group B streptococci* † 5-county	4d	Р	Toxic shock syndrome, non-streptococcal
1wd	L&P	Haemophilus influenzae* †	4d	Р	Trichinosis
4d	L&P	Hantavirus disease	1wd	L&P	Tuberculosis disease (active)*
≈	P	Healthcare-associated infections (HAI)	4d	L	Tuberculosis immune reactivity (+IGRA) <sup>‡</sup>
4d	P	Hemolytic uremic syndrome if < 18 years	1wd	L&P	Tularemia*
1wd	L&P	Hepatitis A (+IgM anti-HAV, +PCR or +NAAT)	1wd	L&P	Typhoid fever*
4d	L&P	Hepatitis B (+HBsAg, +lgM anti- HBc, +HBeAg, or +HBV DNA)	4d	L&P	Varicella (chicken pox)
4d	L&P	Hepatitis C (+ serum antibody titer and/or +confirmatory assays)	4d	L	Vibriosis*
4d	L	Hepatitis C (- confirmatory assays)	lmm	L&P	Viral hemorrhagic fever*
4d	Р	Hepatitis, other viral	4d	L	West Nile virus (acute infection, IgM+)
4d		Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) <sup>®</sup> (All reactive HIV tests, CD4 counts (any value),	4d	L	Yellow fever
			4d	L	Yersiniosis* 7-county
		HIV viral load (any value), HIV genotype)	4d	L	Zika virus

5-county = Adams, Arapahoe, Denver, Douglas and Jefferson 7-county = Adams, Arapahoe, Boulder, Broomfield, Denver, Douglas and Jefferson Boulder = Boulder county only

Time = Time to report | Rep = Reporter

IMM = Immediately (by phone within 4 hours of suspected diagnosis)
24h = 24 hours | 1 wd = 1 working day
4d = 4 calendar days | 30d = 30 calendar days
L = laboratory | P = provider | L&P = both

= = Catheter-associated urinary tract infections (CAUTI) and Methicillin-resistant Staphylococcus aureus bacteremia are reported by conferring rights to the Department to National Healthcare Safety Network (NHSN) data. Additional conditions are reported through NHSN by determination of the HAI Advisory Committee: https://cdphe.colorado.gov/hai. Facilities also report HAIs through voluntary participation in applied public health projects. Reporting timelines vary.

† = positive test from a normally sterile site

‡ = Positive interferon gamma release assays (IGRAs) are only reportable by laboratories that use electronic reporting (ELR).

> = Healthcare providers need to report sex at birth, gender identity, and relevant treatment.

\*\* Submission of isolate/clinical material required. Testing laboratories shall routinely submit bacterial culture isolates or patient clinical material that yields positive findings to the CDPHE Laboratory Services Division. The isolate or clinical material shall be received at the CDPHE Laboratory Services Division no later than one working day after the observation of positive findings. Clinical material is defined as: (i) A culture isolate containing the infectious organism for which submission of material is required, or (ii) If an isolate is not available, material containing the infectious organism for which submission of material is required, in the following order of preference: (A) a patient specimen; (B) nucleic acid; or (C) other laboratory material. For TB, only isolates should be submitted.

Isolate submission for 5-county area only.

## All reports and specimens shall be accompanied by the following information:

8100 Lowry Blvd Denver, CO 80230 Phone: 303-692-3090

- Patient's first and last name
- Patient's date of birth, sex, race, ethnicity Patient's home address, phone and email Patient's preferred language

Name of disease or condition
 Healthcare provider's name, address and phone number
 Laboratory information (test name, collection date, specimen type, accession number and result)



# **Environmental Reportable Conditions**

Effective January 14, 2018

Confidential fax: 303-782-0338 Toll-free fax: 800-811-7263

Phone: 303-692-2700

Toll-free phone: 800-866-2759

Evening/weekend hours: 303-370-9395

Immediate reporting by phone is required of any illness that may be caused by biological, chemical or radiologic terrorism.

As indicated below, reporting by health care providers, laboratories, coroners, hospitals and community clinics with emergency rooms is required in accordance with Regulation 6 CCR 1009-7.

Time	Rep		Time	Rep		
7d	L&P	Blood Lead Levels if ≤18 years (≥5 µg/dL)	90d	Od L&P	Chromosomal abnormalities and neural tube defects diagnosed by prenatal testing or by genetic testing in Colorado residents	
30d	L&P	Blood Lead Levels if ≤18 years (<5 µg/dL)			through the 3 <sup>rd</sup> birthday	
30d	L&P	Blood Lead Levels if >18 years ( $\geq 5~\mu g/dL$ )	24h	L&P	Any other disease, syndrome or condition that is known or suspected to be related to an exposure to a toxic substance,	
30d	L&P	Mercury (Blood, $> 0.5 \mu g/dL$ )			prescription drug, over-the-counter medication or remedy, controlled substance, environmental media or contaminated	
30d	L&P	Mercury (Urine, > 20 μg/L)			product that results in hospitalization, treatment in an emergency department, or death, and is:	
					<ul> <li>a) Suspected of being a cluster, outbreak or epidemic,</li> <li>b) A risk to the public due to ongoing exposure,</li> <li>c) At an increased incidence beyond expectations,</li> <li>d) Due to exposure to food, environmental media (including water, air, soil or sediment), or other material, such as marijuana products, that is contaminated by a toxic substance, hazardous substance, pollutant or contaminant,</li> <li>e) A case of a newly-recognized or emerging disease or syndrome,</li> <li>f) Related to a healthcare setting or contaminated medical devices or products, such as diverted drugs, or</li> <li>g) May be caused by, or related to, a suspected intentional or unintentional release of chemical or radiological agents.</li> </ul>	

24h = 24 hours L = laboratory • Patient's first and last name • Name	All reports and specimens shall be accompanied by the following information:						
7d = 7 calendar days 30d = 30 calendar days 4P = provider L&P = both 5 Patient's date of birth, sex, race, ethnicity 5 Ethnicity 6 Ethnicity	ame of disease or condition ealthcare provider's name, address and phone number aboratory information (test name, collection date, pecimen type, accession number and result)						